World wide experience with inactivated poliovirus vaccine.
As part of the global poliovirus eradication strategy, oral poliovirus vaccine (OPV) has successfully contributed to reduce polio incidence rates globally. However, because of the OPV-related risks of vaccine associated paralytic poliomyelitis (VAPP) and vaccine-derived polioviruses (VDPVs) OPV cessation is required in order to achieve complete eradication of polio. Inactivated poliovirus vaccine (IPV) is a viable option for incorporation into existing vaccination schedules so as to avoid these risks. Furthermore, the continuation of vaccination with IPV will protect populations in case of re-emergence of wild-type poliovirus from remote locations, laboratory samples, or through bioterrorism. The ability of IPV to prevent poliovirus outbreaks and provide herd protection has been demonstrated in several circumstances and in various settings. This paper reviews clinical experiences with IPV administration and outcomes in various countries in Europe, the Americas, Africa and Asia.
Bonnet
Marie-Claude
MC
Global Scientific and Medical Affairs, Sanofi Pasteur, Lyon, France. Marie-Claude.Bonnet@sanofipasteur.com
Dutta
Anil
A
D014943:Global Health; D006801:Humans; D017589:Immunization Programs; D007115:Immunization Schedule; D011051:Poliomyelitis / Q000453:epidemiology / Q000517:prevention & control*; D017955:Poliovirus / Q000276:immunology; D011054:Poliovirus Vaccine, Inactivated / Q000008:administration & dosage*; D011055:Poliovirus Vaccine, Oral / Q000008:administration & dosage / Q000009:adverse effects; D018570:Risk Assessment
D011054:Poliovirus Vaccine, Inactivated; D011055:Poliovirus Vaccine, Oral